➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Baxter
Mallinckrodt
Johnson and Johnson
Dow

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IXEMPRA KIT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ixempra Kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00021099 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed National Cancer Institute (NCI) Phase 2 2001-06-01 Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
NCT00022542 BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma Terminated National Cancer Institute (NCI) Phase 2 2001-06-01 Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00023946 BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Terminated National Cancer Institute (NCI) Phase 2 2001-08-01 Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00025155 Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy Completed National Cancer Institute (NCI) Phase 2 2002-07-01 Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00028561 BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors Terminated National Cancer Institute (NCI) Phase 1 2001-10-01 This phase I trial is studying the side effects and best dose of BMS-247550 when given together with carboplatin in treating patients with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
NCT00033618 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed National Cancer Institute (NCI) Phase 2 2002-11-01 Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ixempra Kit

Condition Name

Condition Name for Ixempra Kit
Intervention Trials
Metastatic Breast Cancer 8
Breast Cancer 6
Stage IV Breast Cancer 5
Recurrent Breast Cancer 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ixempra Kit
Intervention Trials
Breast Neoplasms 19
Carcinoma 8
Adenocarcinoma 6
Endometrial Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ixempra Kit

Trials by Country

Trials by Country for Ixempra Kit
Location Trials
United States 280
Italy 18
Japan 18
United Kingdom 15
Brazil 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ixempra Kit
Location Trials
Maryland 15
California 14
Florida 14
Illinois 11
Missouri 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ixempra Kit

Clinical Trial Phase

Clinical Trial Phase for Ixempra Kit
Clinical Trial Phase Trials
Phase 3 4
Phase 2 31
Phase 1/Phase 2 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ixempra Kit
Clinical Trial Phase Trials
Completed 36
Terminated 9
Active, not recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ixempra Kit

Sponsor Name

Sponsor Name for Ixempra Kit
Sponsor Trials
National Cancer Institute (NCI) 24
Bristol-Myers Squibb 16
R-Pharm 9
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ixempra Kit
Sponsor Trials
Industry 32
NIH 24
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
McKesson
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.